Filing Flows › Gilead Sciences (GILD) › Q2 2026
Gilead Sciences (GILD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Gilead Sciences (GILD) reported revenue of $7.8B for the second quarter 2026 (Q2 2026), +10% from a year earlier and +12% from the quarter before. Operating margin was -133.2%, net loss $10.5B (134.5% of revenue).
Gilead Sciences, Q2 2026: revenue $7.8B (+10% year over year), operating margin -133.2%, net loss $10.5B, operating cash flow $3.6B. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.8B | +12% | +10% |
| Operating profit | −$10.4B | -502% | -520% |
| Net earnings | −$10.5B | -619% | -636% |
| Operating cash flow | $3.6B | +40% | +332% |
| Free cash flow | $3.4B | — | +377% |
What changed
Revenue was $7.8B in Q2 2026, up 10% year over year and up 12% from the previous quarter. Biktarvy was the largest line at 48% of revenue. Biktarvy added $0.24B year over year (up 7%), 34% of the total change. Genvoya declined 23%.
Operating costs exceeded revenue by $10.4B, an operating margin of -133.2%. Total costs grew 295% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+5053%). The quarter ended with a net loss of $10.5B, after a profit of $2.0B the previous quarter.
Operating cash flow was $3.6B (up 332% year over year). Non-cash charges added back $0.10B of depreciation and $0.23B of share-based compensation. Working capital and other items added $13.7B. After purchases of property, plant and equipment ($0.14B), free cash flow as the company reports it was $3.4B.
Questions
What was Gilead Sciences' revenue in the second quarter 2026?
Gilead Sciences (GILD) reported revenue of $7.8B for the second quarter 2026 (Q2 2026), +10% from a year earlier and +12% from the quarter before.
Was Gilead Sciences profitable in the second quarter 2026?
Operating loss was $10.4B (-133.2% of revenue) and net loss $10.5B.
Source: Gilead Sciences 10-Q on SEC EDGAR.